Supplemental Preliminary Amdt. dated August 31, 2006

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claim 1 (original): A cell for expressing serotonin (5HT) isolated from a human NT2 cell line.

Claim 2 (original): A cell for expressing gamma-aminobutyric acid (GABA) isolated from a human NT2 cell line.

Claim 3 (original): A cell for expressing serotonin (5HT) cloned from a cell obtained from a human NT2 cell line.

Claim 4 (original): A cell for expressing gamma-aminobutyric acid (GABA) cloned from a cell obtained from a human NT2 cell line.

Claim 5 (original): A method of treating a neurological disease, condition, or disorder, comprising:

administering to a subject in need thereof a suitable amount of serotonin (5HT) expressing hNT2 cells.

Supplemental Preliminary Amdt. dated August 31, 2006

Claim 6 (original): The method of Claim 5, wherein:

the hNT2 cells are transplanted in or adjacent to the spinal cord of the subject.

Claim 7 (original): The method of Claim 5, wherein:

the hNT2 cells are transplanted in or adjacent to the brain of the subject.

Claim 8 (original): The method of Claim 5, wherein:

the hNT2 cells are transplanted at a location in or adjacent to the central or peripheral nervous system of the subject.

Claim 9 (original): A method of treating a neurological disease, condition, or disorder, comprising:

administering to a subject in need thereof a suitable amount of gamma-aminobutyric acid (GABA) expressing hNT2 cells.

Claim 10 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted in or adjacent to the spinal cord of the subject.

Supplemental Preliminary Amdt. dated August 31, 2006

Claim 11 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted in or adjacent to the brain of the subject.

Claim 12 (original): The method of Claim 9, wherein:

the hNT2 cells are transplanted at a location in or adjacent the central or peripheral nervous system of the subject.

Claim 13 (original): A composition for treating a neurological disease, condition, or disorder, comprising:

- a cell for expressing a bioagent selected from the group consisting of serotonin (5HT), and gamma-aminobutyric acid (GABA), the cell having been isolated from a human NT2 cell line; and
- b) a suitable carrier.

Claim 14 (original): The composition of Claim 13, wherein:

 the neurological disease, condition, or disorder comprises one or more of pain, spasticity, epilepsy, depression, mobility disorder, sensory disorder,
Parkinson's, or Alzheimer's disease.

Supplemental Preliminary Amdt. dated August 31, 2006

Claim 15 (original): A composition for treating a neurological disease, condition, or disorder, comprising:

- a) a cell expressing a bioagent selected from the group consisting of serotonin (5HT), and gamma-aminobutyric acid (GABA), the cell having been cloned from a cell obtained from a human NT2 cell line; and
- b) a suitable carrier.

Claim 16 (original): The composition of Claim 15, wherein:

 the neurological disease, condition, or disorder comprises one or more of pain, spasticity, epilepsy, depression, mobility disorder, sensory disorder,
Parkinson's, or Alzheimer's disease.

Claim 17 (original): A method of producing a mammal useful for studying a neurological disease, condition, and/or disorder, comprising:

transplanting a suitable amount of serotonin expressing human NT2 cells into or near a mammal's spinal cord, brain, or peripheral nervous system.

Claim 18 (original): The method of Claim 17, wherein the mammal is a rodent.

Supplemental Preliminary Amdt. dated August 31, 2006

Claim 19 (original): A rodent produced in accordance with the method of Claim 17.

Claim 20 (original): A method of producing a mammal useful for studying a neurological disease, condition, or disorder, comprising:

transplanting a suitable amount of gamma-aminobutyric acid (GABA) expressing human NT2 cells into or near a mammal's spinal cord, brain, or peripheral nervous system.

Claim 21 (original): The method of Claim 20, wherein the mammal is a rodent.

Claim 22 (original): A rodent produced in accordance with the method of Claim 20.

Claim 23 (original): A cell transplant material, comprising:

a) serotonin expressing human NT2 cells.

Claim 24 (original): A cell transplant material, comprising:

gamma-aminobutyric acid (GABA) expressing human NT2 cells.

Supplemental Preliminary Amdt. dated August 31, 2006

Claim 25 (new): A cell for expressing serotonin (5HT) deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7153.

Claim 26 (new): A cell for expressing gamma-aminobutyric acid (GABA) deposited with the American Type Culture Collection (ATCC) Manassas, Virginia (USA), under Designation No. PTA-7154.